Efficacy and safety of PARP inhibitors in advanced or recurrent endometrial cancer: a systematic review and meta-analysis.

ABSTRACT:

Objective

Several clinical trials have explored the efficacy and safety of Poly (ADP-ribose) polymerase (PARP) inhibitors in endometrial cancer (EC). However, evidence supporting PARP inhibitors alone or in combination with other medications in advanced or recurrent EC remains limited.

Methods

We utilized Cochrane Library, PubMed, Web of Science, and Embase to identify clinical trials that evaluated the efficacy and safety of PARP inhibitors in advanced and recurrent EC. The outcomes analyzed included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and adverse events (AEs). We computed hazard ratios (HRs) for PFS and OS, with 95% confidence intervals (CIs) from randomized trials. Subgroup analysis was conducted based on the PARP inhibit

SUBMITTER: Zhang H 

PROVIDER: S-EPMC12819624 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature